On June 3, Ali Health fell 3.14% in regular trading, trading at HK$3.7/share, with trading volume of HK$129 million, retreating again after a brief rebound in the prior session.

On the news front, the stock continues to face post-earnings selling pressure after the company reported FY26 second-half revenue growth of just 7.6%, significantly below market expectations of 13.8%. Following the results, major banks including UBS, Goldman Sachs, CLSA, and Bank of America collectively lowered their target prices and earnings forecasts, with UBS maintaining a Sell rating and cutting its target to HK$3.6. Meanwhile, newly issued prescription drug online retail guidelines that strictly prohibit AI-assisted prescription review and restrict prescription drug promotions are expected to increase compliance costs for pharmaceutical e-commerce platforms, weighing on near-term profitability.

Within the Internet and Direct Marketing Retail sector, the broader group declined in tandem. Among peers, BABA-W fell 2.98%, Meituan fell 5.32%, JD-SW fell 3.16%, JD Health fell 3.32%, and PA Good Doctor fell 2.66%, reflecting sector-wide linkage effects that amplified pressure on individual names.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)